NIH Reporter #3R01AI195133-01S1

NIAID Solicitation for HISTO-FACT Clinical Trial Participation and Research Services

This opportunity is a solicitation from the National Institute of Allergy and Infectious Diseases (NIAID), under the National Institutes of Health (NIH), for participation in the HISTO-FACT clinical trial focused on histoplasmosis treatment in HIV patients. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - Purpose: - Soliciting applications for a Phase III clinical trial (HISTO-FACT) to evaluate therapies for histoplasmosis in HIV patients - Study to be conducted at the University of Minnesota, Minneapolis - Products/Services Requested: - Clinical trial participation and research services - Therapies to be evaluated include high-dose liposomal amphotericin B and posaconazole - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Unique/Notable Requirements: - Focus on therapies that may influence future treatment guidelines for histoplasmosis - No detailed product line items, part numbers, or quantities provided - Emphasis on research and clinical trial execution, not product procurement

Description

This is a Phase III clinical trial funded by NIH/NIAID to evaluate therapies for histoplasmosis in HIV patients. The study includes high-dose liposomal amphotericin B and posaconazole as treatment options. The trial aims to potentially change treatment guidelines for histoplasmosis. The study location is the University of Minnesota in Minneapolis, MN.

View original listing